Literature DB >> 24935428

HDL in innate and adaptive immunity.

Alberico Luigi Catapano1, Angela Pirillo2, Fabrizia Bonacina3, Giuseppe Danilo Norata4.   

Abstract

During infections or acute conditions high-density lipoproteins cholesterol (HDL-C) levels decrease very rapidly and HDL particles undergo profound changes in their composition and function. These changes are associated with poor prognosis following endotoxemia or sepsis and data from genetically modified animal models support a protective role for HDL. The same is true for some parasitic infections, where the key player appears to be a specific and minor component of HDL, namely apoL-1. The ability of HDL to influence cholesterol availability in lipid rafts in immune cells results in the modulation of toll-like receptors, MHC-II complex, as well as B- and T-cell receptors, while specific molecules shuttled by HDL such as sphingosine-1-phosphate (S1P) contribute to immune cells trafficking. Animal models with defects associated with HDL metabolism and/or influencing cell cholesterol efflux present features related to immune disorders. All these functions point to HDL as a platform integrating innate and adaptive immunity. The aim of this review is to provide an overview of the connection between HDL and immunity in atherosclerosis and beyond. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  HDL; Immunity; Lipid rafts; Macrophages

Mesh:

Substances:

Year:  2014        PMID: 24935428     DOI: 10.1093/cvr/cvu150

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  75 in total

1.  High-density lipoprotein attenuates Th1 and th17 autoimmune responses by modulating dendritic cell maturation and function.

Authors:  Ioanna Tiniakou; Elias Drakos; Vaios Sinatkas; Miranda Van Eck; Vassilis I Zannis; Dimitrios Boumpas; Panayotis Verginis; Dimitris Kardassis
Journal:  J Immunol       Date:  2015-04-13       Impact factor: 5.422

2.  Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study.

Authors:  Peter Penson; D Leann Long; George Howard; Virginia J Howard; Steven R Jones; Seth S Martin; Dimitri P Mikhailidis; Paul Muntner; Manfredi Rizzo; Daniel J Rader; Monika M Safford; Amirhossein Sahebkar; Peter P Toth; Maciej Banach
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

Review 3.  Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology.

Authors:  José Tuñón; Lina Badimón; Marie-Luce Bochaton-Piallat; Bertrand Cariou; Mat J Daemen; Jesus Egido; Paul C Evans; Imo E Hoefer; Daniel F J Ketelhuth; Esther Lutgens; Christian M Matter; Claudia Monaco; Sabine Steffens; Erik Stroes; Cécile Vindis; Christian Weber; Magnus Bäck
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

Review 4.  Emerging risk biomarkers in cardiovascular diseases and disorders.

Authors:  Ravi Kant Upadhyay
Journal:  J Lipids       Date:  2015-04-08

Review 5.  Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.

Authors:  Giuseppe Danilo Norata; Hagai Tavori; Angela Pirillo; Sergio Fazio; Alberico L Catapano
Journal:  Cardiovasc Res       Date:  2016-08-05       Impact factor: 10.787

6.  A modified ketogenic gluten-free diet with MCT improves behavior in children with autism spectrum disorder.

Authors:  Ryan W Y Lee; Michael J Corley; Alina Pang; Gaye Arakaki; Lisa Abbott; Michael Nishimoto; Rob Miyamoto; Erica Lee; Susan Yamamoto; Alika K Maunakea; Annette Lum-Jones; Miki Wong
Journal:  Physiol Behav       Date:  2018-02-05

Review 7.  The A's Have It: Developing Apolipoprotein A-I Mimetic Peptides Into a Novel Treatment for Asthma.

Authors:  Xianglan Yao; Elizabeth M Gordon; Amisha V Barochia; Alan T Remaley; Stewart J Levine
Journal:  Chest       Date:  2016-06-18       Impact factor: 9.410

8.  Cholesterol-Independent Suppression of Lymphocyte Activation, Autoimmunity, and Glomerulonephritis by Apolipoprotein A-I in Normocholesterolemic Lupus-Prone Mice.

Authors:  Leland L Black; Roshni Srivastava; Trenton R Schoeb; Ray D Moore; Stephen Barnes; Janusz H Kabarowski
Journal:  J Immunol       Date:  2015-10-14       Impact factor: 5.422

9.  Site-specific 5-hydroxytryptophan incorporation into apolipoprotein A-I impairs cholesterol efflux activity and high-density lipoprotein biogenesis.

Authors:  Maryam Zamanian-Daryoush; Valentin Gogonea; Anthony J DiDonato; Jennifer A Buffa; Ibrahim Choucair; Bruce S Levison; Randall A Hughes; Andrew D Ellington; Ying Huang; Xinmin S Li; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2020-02-25       Impact factor: 5.157

Review 10.  From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease.

Authors:  Frank M Sacks; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-25       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.